Results 91 to 100 of about 122,145 (339)

Frailty and Cardiovascular Events as Determined by Body Composition: A Systematic Review

Chronic Diseases and Translational Medicine, EarlyView.
Frailty phenotypes and risk of cardiovascular disease. Sarcopenic obese phenotype is associated with increased prevalence of cardiovascular risk factors and progression of metabolic syndrome, leading to cardiovascular events and cardiovascular mortality, while the Anorexic malnourished phenotype is associated with reduced prevalence of cardiovascular ...
Ishleen Oberoi, Shabnam Tariq, Kristian Arak, Mhd Alaa Aldin Al‐Haffar, Kyaw Thet, Ahmed H. Abdelhafiz   +5 more
wiley   +1 more source

A narrative review of glucagon-like peptide-1 receptor agonists prior to deep sedation or general anesthesia

Journal of Anesthesia, Analgesia and Critical Care
Glucagon-like peptide-1 receptor agonists are a class of drugs that mimic a natural incretin hormone released by the intestine after meals, and they are well-suited for treating type 2 diabetes.
Luigi Vetrugno, Cristian Deana, Andrea Da Porto, Enrico Boero, Valentina Bellini, Daniele Guerino Biasucci, Elena Giovanna Bignami   +6 more
doaj   +1 more source

Diabetes and obesity. The role of agonists glucagon-like peptide-1 of in the treatment of type 2 diabetes

Сахарный диабет, 2018
Significant number of patients with type 2 diabetes mellitus are obese. It is known that even glucose intolerance, as well as diabetes, can lead to vascular complications.
Nina A. Petunina, Milena Е. Telnova
doaj   +1 more source

Extracellular loops 2 and 3 of the calcitonin receptor selectively modify agonist binding and efficacy. [PDF]

, 2018
Class B peptide hormone GPCRs are targets for the treatment of major chronic disease. Peptide ligands of these receptors display biased agonism and this may provide future therapeutic advantage.
Andreassen, Arthur Christopoulos, Baldwin, Barwell, Belcheva, Berendsen, Black, Booe, Caroline A. Hick, Christopher A. Reynolds, Christopoulos, Christopoulos, Cosman, Dal Maso, de Graaf, Debbie L. Hay, Dehua Yang, Denise Wootten, Doerr, Dolinsky, Dong, Dong, Emma Dal Maso, Epand, Essmann, Eswar, Feyen, Furness, Gingell, Giuseppe Deganutti, Hamelryck, Harikumar, Harvey, Hay, Hilton, Huang, Humphrey, Johansson, Jorgensen, Koole, Koole, Krautler, Kuestner, Kuwasako, Kuwasako, Langston, Li, Liang, Lomize, Loncharich, Ming-Wei Wang, Minhas, Morfis, Orlowski, Patrick M. Sexton, Poyner, Sebastian G.B. Furness, Sommer, Udawela, Udawela, Vi Pham, Watkins, Weaver, Weston, Weston, Woolley, Woolley, Wootten, Wootten, Yue Zhu, Zhang   +70 more
core   +1 more source

GLP‐1 Receptor Agonists in Metabolic Dysfunction‐Associated Steatotic Liver Disease: Bridging Hepatic and Cardiovascular Outcomes

Chronic Diseases and Translational Medicine, EarlyView.
Endogenous GLP‐1 and exogenous GLP‐1 RAs activate GLP‐1R‐expressing vagal afferents in the portal vein, projecting to the nucleus tractus solitarius (NTS). This input engages brainstem–hypothalamic circuits that regulate metabolic homeostasis. Hypothalamic efferent vagal output to the liver suppresses lipogenesis, enhances triglyceride export, and ...
Gabriel Amorim Moreira Alves, Masatoki Teranishi, Rajendranandini Majumdar, Fazal Khan, Mohan Dodeja, Ana Claudia Teixeira de Castro Gonçalves Ortega, Marco Acerboni, Arosh S. Perera Molligoda Arachchige, Frank James   +8 more
wiley   +1 more source

Recent clinical and pharmacological advancements of incretin-based therapy and the effects of incretin on physiology

Journal of Diabetology
A novel therapeutic target for diabetes mellitus is incretin-based therapies, glucagon-like peptide-1, and glucose-dependent insulinotropic polypeptides are released from the gastrointestinal (GI) tract and act on beta cells of pancreatic islets by ...
Bhaskar Pal, Moitreyee Chattopadhyay
doaj   +1 more source

Small-molecule agonists for the glucagon-like peptide 1 receptor [PDF]

Proceedings of the National Academy of Sciences, 2007
The peptide hormone glucagon-like peptide (GLP)-1 has important actions resulting in glucose lowering along with weight loss in patients with type 2 diabetes. As a peptide hormone, GLP-1 has to be administered by injection. Only a few small-molecule agonists to peptide hormone receptors have been described and none in the B family of the G protein ...
Knudsen, Lotte Bjerre, Kiel, Dan, Teng, Min, Behrens, Carsten, Bhumralkar, Dilip, Kodra, János T, Holst, Jens Juul, Jeppesen, Claus B, Johnson, Michael D, de Jong, Johannes Cornelis, Jorgensen, Anker Steen, Kercher, Tim, Kostrowicki, Jarek, Madsen, Peter, Olesen, Preben H, Petersen, Jacob S, Poulsen, Fritz, Sidelmann, Ulla G, Sturis, Jeppe, Truesdale, Larry, May, John, Lau, Jesper   +21 more
openaire   +3 more sources

A Systematic Review on Disease‐Modifying Therapies in Parkinsonian Disorders

Clinical Pharmacology &Therapeutics, EarlyView.
Parkinsonian disorders, including Parkinson's disease, Lewy body dementia, multiple system atrophy, and progressive supranuclear palsy, are progressive neurodegenerative conditions with no treatment options to slow disease progression. This systematic review provides an overview of evidence of disease‐modifying therapies that have been evaluated in ...
Pepijn P.N.M. Eijsvogel, Lars M.G. Smits, Philip H.C. Kremer, Geert Jan Groeneveld   +3 more
wiley   +1 more source

Differential hypoglycaemic, anorectic, autonomic and emetic effects of the glucagon-like peptide receptor agonist, exendin-4, in the conscious telemetered ferret. [PDF]

, 2014
Background: Rodents are incapable of emesis and consequently the emetic potential of glucagon-like peptide-1 receptor (GLP-1R) agonists in studies designed to assess a potential blood glucose lowering action of the compound was missed.
A Amato, A Flint, A Rotondo, A Vella, A Wettergren, AD Farmer, AH Barnett, AM Holmes, B Kreymann, BD Kiernan, BP Bullock, C Tourrel, CA Richards, Chi-Kong Yeung, CM Edwards, CR Abbott, David TW Yew, DD De Leon, Ge Lin, GJ Sanger, GM Holmes, GR Morrow, I Billig, I Doweck, INC Lawes, J Kim, JA Kim, JL Iltz, JL Lachey, JM Egan, John A Rudd, JP Gutzwiller, JP Gutzwiller, JP Gutzwiller, K Venkova, KE Mayo, KP Kinzig, L Van Bloemendaal, L Zheng, LL Baggio, LT LaCount, M Reardon, MM Combettes, N Imeryuz, N Percie Du Sert, N Percie du Sert, N Percie Du Sert, NA Gupta, Nathalie Percie Du Sert, NH Greig, P Bhandari, Paul LR Andrews, PJ Gianaros, PJ Shughrue, PL Andrews, R Goke, R Goke, R Shirazi, RM Stern, S Madsbad, SE Ayachi, SE Kanoski, SW Chan, SW Chan, SW Chan, Sze Wa Chan, T Perry, T Tolessa, T Tolessa, V Bucinskaite, Y Wei, Zengbing Lu   +71 more
core   +1 more source

Diffuse Podocytopathy Associated With Semaglutide

Annals of Internal Medicine: Clinical Cases
We present 3 cases of biopsy-proven minimal change disease occurring in close temporal association with semaglutide (glucagon-like peptide 1 receptor agonists) exposure.
Rose Mary Attieh, Grant Kirby, Yang Yihe, Serena Bagnasco, Andrew A. Moses, Mahmoud Abdelaziz, Rimda Wanchoo, Samir Gautam, Astrid Weins, Kenar D. Jhaveri   +9 more
doaj   +1 more source